Eli Lilly and Company (BIT:1LLY)

Market Cap	575.00B
Revenue (ttm)	45.35B
Net Income (ttm)	11.75B
Shares Out	n/a
EPS (ttm)	13.02
PE Ratio	48.93
Forward PE	26.71
Dividend	5.30 (0.83%)
Ex-Dividend Date	Aug 14, 2025

Volume	236
Average Volume	1,250
Open	641.80
Previous Close	638.80
Day's Range	639.60 - 642.00
52-Week Range	535.20 - 888.00
Beta	n/a
RSI	55.24
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD